Clinical trial findings showed Avance was noninferior to a collagen nerve cuff for returning sensory function in patients with nerve injuries in the hand. The Food and Drug Administration (FDA) has ...
19d
Humacyte (HUMA) Is Up 23.8% After Long-Term Self-Repair Dialysis Data - Has The Bull Case Changed?
Humacyte recently reported research showing its acellular tissue engineered vessel (ATEV) used for dialysis access can self-repair after repeated needle cannulation, maintaining structural integrity ...
Humacyte Inc. HUMA stock plunged Thursday despite reporting positive interim Phase 3 data for its acellular tissue-engineered ...
In a trial, an acellular tissue engineered vessel had superior functional patency for hemodialysis with acceptable safety compared with an arteriovenous fistula in high-risk patients. An acellular ...
The U.S. Food and Drug Administration has approved Symvess, the first acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent ...
DURHAM, N.C., July 01, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissues at ...
DURHAM, N.C., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at ...
Risk factors for postoperative complications of a randomized clinical trial: Laparoscopic versus open surgery with D3 lymphadenectomy for stage II/III colon cancer (JCOG0404). Repeated ...
Please provide your email address to receive an email when new articles are posted on . The acellular implant group had statistically significant improvements in overall outcome scores and subscores.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results